When should therapy be reinstituted for relapsed Wegener's granulomatosis?
Sakamoto
Masayuki
M
Department of Otolaryngology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo Bunkyo-ku, Tokyo 113-8655, Japan. sakamoto@rigid.com
Uno
Hideyuki
H
Takagi
Kenji
K
Higo
Ryuzaburo
R
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004844:Epistaxis / Q000188:drug therapy; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000627:therapeutic use; D014890:Granulomatosis with Polyangiitis / Q000188:drug therapy*; D006469:Hemoptysis / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D015508:Nasal Obstruction / Q000188:drug therapy; D009668:Nose Diseases / Q000188:drug therapy*; D011239:Prednisolone / Q000627:therapeutic use; D019233:Retreatment
D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D011239:Prednisolone